Lauren Pankratz, M.D., Carisse Orsi, M.D., Chandra Slusser, and Jane Lynch, M.D.
In this informative case study, the authors describe the transition from insulin to sulfonylurea therapy in the treatment of a 1-month old boy with neonatal diabetes. The article also details how a continuous glucose monitoring system proved valuable in determining the sulfonylurea dose.
Equipment — Continuous glucose monitoring systems
Drug treatment — Sulfonylureas
Rene Oliveros, M.D., F.A.C.C., Mike Lujan, B.S., and Robert Chilton, D.O., F.A.C.C.
Hypertension is a common comorbidity in people with diabetes. The authors review its pathogenesis and treatment and examine the evidence for tighter blood pressure goals.
Complications and comorbidities — Cardiovascular disease — Hypertension
Andrea Torres, M.D., and John E. Nestler, M.D.
Women with polycystic ovary syndrome are at increased risk for impaired glucose tolerance and Type 2 diabetes. Drs. Torres and Nestler review the risk factors, screening, prevention, and treatment of impaired glucose tolerance in this population.
Complications and comorbidities — Polycystic ovary syndrome
Jeanne L. Rosenthal, M.D., M.P.O.D., F.A.C.S.
Up to 20% of people with diabetes report that their condition causes them some vision loss. The most common cause is diabetic retinopathy. Dr. Rosenthal examines the development, pathogenesis, and treatment of retinopathy, offering a clear explanation of the care of patients with retinopathy at each stage of its development. New therapies, including laser treatments and surgeries, are also discussed.
Complications and comorbidities — Retinopathy
Marion J. Franz, M.S., R.D., C.D.E.
Ms. Franz reviews the longstanding debate over the optimal carbohydrate intake for people with diabetes, addressing the following questions: Does high-carbohydrate intake cause insulin resistance? Does a low-carbohydrate diet improve glycemic control? Do carbohydrates increase triglyceride levels? Are high- or low-carbohydrate diets better for weight loss?
Diet therapy and nutrition
Management strategies and tools
Geralyn R. Spollett, M.S.N., A.N.P.-C.S., C.D.E.
Good communication is the foundation of successful diabetes care. But when the provider and the patient speak different languages, it can be difficult for both to get their message across. Ms. Spollett examines the use of interpreters in the health-care setting and gives practical advice on how to work with an interpreter to improve your patient’s care.
Charles A. Reasner, M.D.
Type 2 diabetes is often associated with atherogenic dyslipidemia. Statins are currently the first-line therapy and have been shown to reduce the risk of cardiovascular events by 25% to 30%. Addressing the “residual cardiovascular risk,” however, remains a challenge. The Editor reviews the many drug treatments for reducing this risk, focusing in particular on new results from the ARBITER 6-HALTS and ACCORD trials.
Complications and comorbidities — Cardiovascular disease — Dyslipidemia